{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T20:42:16Z","timestamp":1782506536510,"version":"3.54.5"},"reference-count":107,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T00:00:00Z","timestamp":1726963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Chronic hepatitis C virus (HCV) infection is associated with an increased risk of extrahepatic cancers, particularly non-Hodgkin lymphoma. The introduction of direct-acting antivirals (DAAs) has revolutionized HCV therapy, resulting in high cure rates. However, concerns have been raised about potential effects on cancer risk. This review summarizes the current evidence on extrahepatic cancer risk in HCV-infected patients treated with DAAs. We examined epidemiologic data on HCV-associated extrahepatic cancers and explored potential mechanisms linking HCV to carcinogenesis outside the liver. Studies evaluating cancer outcomes after DAA therapy were critically reviewed while considering methodological challenges. While some studies suggested a reduced risk of extrahepatic cancers after DAA therapy, others showed no significant change. Limitations included short follow-up periods and confounding variables. Immunological changes following rapid HCV clearance may have complex effects on cancer risk. Long-term prospective studies and mechanistic investigations are needed to fully elucidate the relationship between DAA therapy and extrahepatic cancer risk in HCV patients. Clinicians should remain vigilant for extrahepatic malignancies in this population.<\/jats:p>","DOI":"10.3390\/microorganisms12091926","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T04:45:28Z","timestamp":1727066728000},"page":"1926","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Extrahepatic Cancer Risk in Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antivirals"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8801-2505","authenticated-orcid":false,"given":"Joji","family":"Tani","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Takamatsu 761-0793, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Masaki","sequence":"additional","affiliation":[{"name":"Kagawa Saiseikai Hospital, Takamatsu 761-8076, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9531-7240","authenticated-orcid":false,"given":"Kyoko","family":"Oura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Takamatsu 761-0793, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9975-386X","authenticated-orcid":false,"given":"Tomoko","family":"Tadokoro","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Takamatsu 761-0793, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0760-3045","authenticated-orcid":false,"given":"Asahiro","family":"Morishita","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Takamatsu 761-0793, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Kobara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki, Kita, Takamatsu 761-0793, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Tadokoro, T., Tani, J., Morishita, A., Fujita, K., Masaki, T., and Kobara, H. (2024). The Treatment of Hepatocellular Carcinoma with Major Vascular Invasion. Cancers, 16.","DOI":"10.3390\/cancers16142534"},{"key":"ref_2","first-page":"3","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"3","author":"Cacoub","year":"2016","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","article-title":"Extrahepatic morbidity and mortality of chronic hepatitis C","volume":"149","author":"Negro","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrgastro.2017.172","article-title":"Extrahepatic cancers and chronic HCV infection","volume":"15","author":"Pol","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1136\/gutjnl-2017-313983","article-title":"The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection","volume":"67","author":"Mahale","year":"2018","journal-title":"Gut"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2214-109X(16)30143-7","article-title":"Global burden of cancers attributable to infections in 2012: A synthetic analysis","volume":"4","author":"Plummer","year":"2016","journal-title":"Lancet Glob. Health"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"(2018). EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol., 69, 461\u2013511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.dld.2014.10.005","article-title":"Extrahepatic manifestations of chronic hepatitis C virus infection","volume":"46","author":"Cacoub","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.3748\/wjg.v20.i13.3410","article-title":"Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms","volume":"20","author":"Adinolfi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_12","first-page":"2205","article-title":"Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study","volume":"19","author":"Tani","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tani, J., Senoh, T., Moriya, A., Ogawa, C., Deguchi, A., Sakamoto, T., Takuma, K., Nakahara, M., Oura, K., and Tadokoro, T. (2021). Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study. Cancers, 13.","DOI":"10.3390\/cancers13092257"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","article-title":"Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry","volume":"69","author":"Belli","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1053\/j.gastro.2019.01.027","article-title":"Direct-Acting Antiviral Therapy Not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study","volume":"156","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/jvh.13232","article-title":"Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis","volume":"27","author":"McDonald","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.cgh.2008.02.011","article-title":"Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium","volume":"6","author":"Benavente","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/CLEP.S10193","article-title":"Hepatitis C virus infection and risk of cancer: A population-based cohort study","volume":"2","author":"Omland","year":"2010","journal-title":"Clin. Epidemiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/cncr.30559","article-title":"Hepatitis C virus infection and the risk of cancer among elderly US adults: A registry-based case-control study","volume":"123","author":"Mahale","year":"2017","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/liv.14305","article-title":"Increased cancer rates in patients with chronic hepatitis C","volume":"40","author":"Nyberg","year":"2020","journal-title":"Liver Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","article-title":"Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: A meta-analysis of epidemiologic studies","volume":"15","author":"Franceschi","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jhep.2013.03.018","article-title":"Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management","volume":"59","author":"Arcaini","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1365-2036.2005.02395.x","article-title":"Systematic review: Regression of lymphoproliferative disorders after treatment for hepatitis C infection","volume":"21","author":"Gisbert","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13027-024-00577-4","article-title":"Shared genetic factors and causal association between chronic hepatitis C infection and diffuse large B cell lymphoma","volume":"19","author":"Fu","year":"2024","journal-title":"Infect. Agent. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1750-9378-9-10","article-title":"Response to peginterferon plus ribavirin and subsequent retreatment with telaprevir-based triple therapy in a patient with chronic lymphocytic leukaemia and chronic HCV genotype 1b infection","volume":"9","author":"Christensen","year":"2014","journal-title":"Infect. Agent. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12896","DOI":"10.3748\/wjg.v21.i45.12896","article-title":"Possible association between hepatitis C virus and malignancies different from hepatocellular carcinoma: A systematic review","volume":"21","author":"Fiorino","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1038\/bjc.2013.689","article-title":"Risk of pancreatic cancer among individuals with hepatitis C or hepatitis B virus infection: A nationwide study in Sweden","volume":"109","author":"Huang","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.3748\/wjg.v19.i26.4234","article-title":"Hepatitis B or C viral infection and risk of pancreatic cancer: A meta-analysis of observational studies","volume":"19","author":"Xu","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ma, Y., Huang, Z., Jian, Z., and Wei, X. (2021). The association between hepatitis C virus infection and renal cell cancer, prostate cancer, and bladder cancer: A systematic review and meta-analysis. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-90404-2"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2012.02.022","article-title":"Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma","volume":"57","author":"Palmer","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_31","first-page":"3080","article-title":"Hepatitis C accelerates extrahepatic cholangiocarcinoma risk: A joint study of hospital-based cases and nationwide population-based cohorts in a viral hepatitis-endemic area","volume":"13","author":"Huang","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis","volume":"72","author":"Clements","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1089\/thy.2006.0194","article-title":"Thyroid cancer in HCV-related chronic hepatitis patients: A case-control study","volume":"17","author":"Antonelli","year":"2007","journal-title":"Thyroid"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: A community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.22606","article-title":"Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans","volume":"49","author":"Engels","year":"2009","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/ijc.25321","article-title":"Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: Systematic review and meta-analysis","volume":"128","author":"Cho","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1182\/blood-2010-06-275818","article-title":"Hepatitis viruses and non-Hodgkin lymphoma: Epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities","volume":"117","author":"Marcucci","year":"2011","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.critrevonc.2019.04.005","article-title":"Heterogeneity and coexistence of oncogenic mechanisms involved in HCV-associated B-cell lymphomas","volume":"138","author":"Carloni","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/1479-5876-10-158","article-title":"Hepatitis C virus infection in the immunocompromised host: A complex scenario with variable clinical impact","volume":"10","author":"Zignego","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1073\/pnas.0303971101","article-title":"Hepatitis C virus induces a mutator phenotype: Enhanced mutations of immunoglobulin and protooncogenes","volume":"101","author":"Machida","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/ajh.1101","article-title":"Hepatitis C virus infection and lymphoproliferative diseases: Prospective study on 1,576 patients in France","volume":"67","author":"Hausfater","year":"2001","journal-title":"Am. J. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"8910396","DOI":"10.1155\/2016\/8910396","article-title":"Oxidative Stress during HIV Infection: Mechanisms and Consequences","volume":"2016","author":"Ivanov","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Liang, Y., Cao, X., Ding, Q., Zhao, Y., He, Z., and Zhong, J. (2018). Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1007455"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1053\/gast.2002.30983","article-title":"Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein","volume":"122","author":"Okuda","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1007\/s00125-005-1682-x","article-title":"Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: Sites and mechanisms","volume":"48","author":"Bugianesi","year":"2005","journal-title":"Diabetologia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.3748\/wjg.v20.i11.2888","article-title":"Interaction between hepatitis C virus and metabolic factors","volume":"20","author":"Kawaguchi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2003.11.056","article-title":"Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance","volume":"126","author":"Shintani","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1128\/JVI.01672-07","article-title":"Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt\/protein kinase B signaling pathway for insulin resistance","volume":"82","author":"Banerjee","year":"2008","journal-title":"J. Virol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/2053","article-title":"The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice","volume":"4","author":"Moriya","year":"1998","journal-title":"Nat. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8856","DOI":"10.1128\/jvi.71.11.8856-8859.1997","article-title":"Hepatitis C virus nonstructural region 5A protein is a potent transcriptional activator","volume":"71","author":"Kato","year":"1997","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.virol.2007.08.037","article-title":"Hepatitis C virus NS3\/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation","volume":"370","author":"Lai","year":"2008","journal-title":"Virology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jare.2016.06.001","article-title":"Hepatitis C virus and cardiovascular: A review","volume":"8","author":"Petta","year":"2017","journal-title":"J. Adv. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.tim.2003.12.005","article-title":"Pathophysiology of hepatitis C virus infection and related liver disease","volume":"12","author":"Pawlotsky","year":"2004","journal-title":"Trends Microbiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12090","article-title":"Natural killer cells: Multifaceted players with key roles in hepatitis C immunity","volume":"255","author":"Rosen","year":"2013","journal-title":"Immunol. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1172\/JCI39133","article-title":"Hepatitis C virus versus innate and adaptive immune responses: A tale of coevolution and coexistence","volume":"119","author":"Rehermann","year":"2009","journal-title":"J. Clin. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.jhep.2014.06.035","article-title":"Innate and adaptive immune responses in HCV infections","volume":"61","author":"Heim","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/1743-422X-8-346","article-title":"Human cell types important for hepatitis C virus replication in vivo and in vitro: Old assertions and current evidence","volume":"8","author":"Revie","year":"2011","journal-title":"Virol. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2893.2012.01591.x","article-title":"Hepatitis C virus and the brain","volume":"19","author":"Fletcher","year":"2012","journal-title":"J. Viral Hepat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/odi.12803","article-title":"Outcomes of oral lichen planus and oral lichenoid lesions treated with topical corticosteroid","volume":"24","author":"Bravo","year":"2018","journal-title":"Oral. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/hep.26106","article-title":"Rare disease clinical research network\u2019s urea cycle consortium delivers a successful clinical trial to improve alternate pathway therapy","volume":"57","author":"Mistry","year":"2013","journal-title":"Hepatology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","article-title":"Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C","volume":"120","author":"Kawamura","year":"2007","journal-title":"Am. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ioannou, G.N., Green, P.K., and Berry, K. (2017). HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J. Hepatol., online ahead of print.","DOI":"10.1016\/j.jhep.2017.08.030"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ygh2.456","article-title":"Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with direct-acting antivirals","volume":"3","author":"Lybeck","year":"2021","journal-title":"GastroHep"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1053\/j.gastro.2019.06.026","article-title":"Trends in Mortality From Extrahepatic Complications in Patients with Chronic Liver Disease, From 2007 Through 2017","volume":"157","author":"Kim","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep4.1389","article-title":"Eradication of Hepatitis C Virus Is Associated with Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals","volume":"3","author":"Ioannou","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/apt.16081","article-title":"Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US","volume":"52","author":"Wang","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/liv.14119","article-title":"Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: A systematic review and meta-analysis","volume":"39","author":"Masarone","year":"2019","journal-title":"Liver Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamainternmed.2022.5699","article-title":"Association of Direct-Acting Antiviral Therapy with Liver and Nonliver Complications and Long-term Mortality in Patients with Chronic Hepatitis C","volume":"183","author":"Ogawa","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2017.10.033","article-title":"The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen","volume":"68","author":"Innes","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of Hepatocellular Carcinoma in Patients with HCV-Associated Cirrhosis Treated with Direct-Acting Antiviral Agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hep.28535","article-title":"Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection","volume":"64","author":"Kanwal","year":"2016","journal-title":"Hepatology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of Hepatitis C Virus Infection in Patients with Cirrhosis Reduces Risk of Liver and Non-Liver Complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated with Direct-Acting Antiviral Agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.29811","article-title":"Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease","volume":"68","author":"Backus","year":"2018","journal-title":"Hepatology"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/infdis\/jiv391","article-title":"Immunological Analysis during Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment","volume":"213","author":"Spaan","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.gastro.2015.03.004","article-title":"Successful Interferon-Free Therapy of Chronic Hepatitis C Virus Infection Normalizes Natural Killer Cell Function","volume":"149","author":"Serti","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000490360","article-title":"HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection","volume":"8","author":"Schlevogt","year":"2019","journal-title":"Liver Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1093\/infdis\/jiw457","article-title":"Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients with Chronic Hepatitis C","volume":"214","author":"Hengst","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Burchill, M.A., Roby, J.A., Crochet, N., Wind-Rotolo, M., Stone, A.E., Edwards, M.G., Dran, R.J., Kriss, M.S., Gale, M., and Rosen, H.R. (2017). Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0186213"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Khanam, A., Kottilil, S., and Wilson, E. (2020). Reconstitution of T follicular helper-humoral immune axis with elimination of hepatitis C virus. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-77020-2"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"(2016). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J. Hepatol., 65, 734\u2013740.","DOI":"10.1016\/j.jhep.2016.05.045"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality in Patients with Advanced Liver Disease","volume":"69","author":"Backus","year":"2019","journal-title":"Hepatology"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Bezemer, G., Van Gool, A.R., Verheij-Hart, E., Hansen, B.E., Lurie, Y., Esteban, J.I., Lagging, M., Negro, F., Zeuzem, S., and Ferrari, C. (2012). Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterol., 12.","DOI":"10.1186\/1471-230X-12-11"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/hep.27743","article-title":"Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)","volume":"62","author":"Trinchet","year":"2015","journal-title":"Hepatology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"101691","DOI":"10.1016\/j.canep.2020.101691","article-title":"Hepatitis C virus infection and risk of pancreatic cancer: A meta-analysis","volume":"65","author":"Arafa","year":"2020","journal-title":"Cancer Epidemiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1158\/1055-9965.EPI-21-0742","article-title":"Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk before and after Introduction of Direct-Acting Antivirals","volume":"30","author":"Lam","year":"2021","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1136\/gutjnl-2018-316234","article-title":"Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: A meta-analysis","volume":"67","author":"Cacoub","year":"2018","journal-title":"Gut"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2019.07.040","article-title":"Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated with Increased Survival in Patients with a History of Hepatocellular Carcinoma","volume":"157","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/hep.29364","article-title":"Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma","volume":"67","author":"Persico","year":"2018","journal-title":"Hepatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: A study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/liv.12391","article-title":"Management of HCV patients with cirrhosis with direct acting antivirals","volume":"34","author":"Boccaccio","year":"2014","journal-title":"Liver Int."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Jang, J.W., Kim, J.S., Kim, H.S., Tak, K.Y., Lee, S.K., Nam, H.C., Sung, P.S., Kim, C.M., Park, J.Y., and Bae, S.H. (2021). Significance of TERT Genetic Alterations and Telomere Length in Hepatocellular Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13092160"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Baumert, T.F., J\u00fchling, F., Ono, A., and Hoshida, Y. (2017). Hepatitis C-related hepatocellular carcinoma in the era of new generation antivirals. BMC Med., 15.","DOI":"10.1186\/s12916-017-0815-7"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.cgh.2007.02.039","article-title":"Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis","volume":"5","author":"Ioannou","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J. Hepatol."},{"key":"ref_99","first-page":"35","article-title":"Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma","volume":"6","author":"Benhammou","year":"2020","journal-title":"Hepatoma Res."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jval.2013.07.006","article-title":"Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States","volume":"16","author":"Chhatwal","year":"2013","journal-title":"Value Health"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/apt.13081","article-title":"Cost-effectiveness of all-oral ledipasvir\/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection","volume":"41","author":"Younossi","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/hep.29399","article-title":"Modeling cost-effectiveness and health gains of a \u201cuniversal\u201d versus \u201cprioritized\u201d hepatitis C virus treatment policy in a real-life cohort","volume":"66","author":"Kondili","year":"2017","journal-title":"Hepatology"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/infdis\/jit827","article-title":"IFNL4-\u0394G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin","volume":"209","author":"Meissner","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2014.05.043","article-title":"Restoration of HCV-specific CD8+ T cell function by interferon-free therapy","volume":"61","author":"Martin","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/hep.29911","article-title":"Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer after Hepatitis C Virus Direct-Acting Antivirals","volume":"68","author":"Faillaci","year":"2018","journal-title":"Hepatology"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Debes, J.D., Romagnoli, P.A., Prieto, J., Arrese, M., Mattos, A.Z., Boonstra, A., and On Behalf of the Escalon, C. (2021). Serum Biomarkers for the Prediction of Hepatocellular Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13071681"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Cabral, L.K.D., Grisetti, L., Pratama, M.Y., Tiribelli, C., and Pascut, D. (2022). Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals. Cancers, 14.","DOI":"10.3390\/cancers14112700"}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/9\/1926\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:02:04Z","timestamp":1760112124000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/12\/9\/1926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,22]]},"references-count":107,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["microorganisms12091926"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms12091926","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,22]]}}}